Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
This study has been completed.
First Posted: January 17, 2007
Last Update Posted: October 24, 2012
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||January 2008|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||July 11, 2012|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Morimoto BH, Schmechel D, Hirman J, Blackwell A, Keith J, Gold M; AL-108-211 Study. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement Geriatr Cogn Disord. 2013;35(5-6):325-36. doi: 10.1159/000348347. Epub 2013 Apr 13.